Nasdaq ardx.
Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ...
Dec 13, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ... WALTHAM, Mass., Dec. 29, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U ...Nov 20, 2023 · Ulysses Erickson. November 20, 2023. In the latest trading session, 1.04 million Ardelyx Inc (NASDAQ:ARDX) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $4.30 changed hands at -$0.03 or -0.69% at last look, the market valuation stands at $998.20M. ARDX’s current price is a ... The restructuring drive implemented on August 02 is intended “to reduce operating costs and better align the Company’s workforce with the needs of its business,” Ardelyx (NASDAQ:ARDX) said ...Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.
Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago.
Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ...
Ardelyx, Inc. (NASDAQ:NASDAQ:ARDX) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ETCompany ParticipantsCaitlin Lowie - Vice President of... Oct 31, 2023 seekingalpha.comWALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, …Ardelyx Inc (NASDAQ: ARDX) Ardelyx is a biotech penny stock which already has a successful product on the market . Ibsrela (tenapanor) is a drug that was introduced by the company in March 2022. It is used …
Health care stocks were finishing near their Friday highs this afternoon, with the NYSE Health Care Index rising 1.0% while the Health Care Select Sector SPDR Fund (XLV) was up 0.9%.
According to the issued ratings of 5 analysts in the last year, the consensus rating for Ardelyx stock is Buy based on the current 5 buy ratings for ARDX. The average twelve-month price prediction for Ardelyx is $8.70 with a high price target of $11.00 and a low price target of $7.00. Learn more on ARDX's analyst rating history.
Find the latest Insider Activity data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. Principal Financial Group Inc. acquired a new stake in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 24,269 shares of the biopharmaceutical company’s stock, valued at approximately $82,000. …Nov 24, 2023 · Who is on Ardelyx's Insider Roster? The list of insiders at Ardelyx includes David M. Mott, David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell, and Susan Rodriguez. Learn more on insiders at ARDX. Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.ARDELYX INC ( ARDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ardelyx’s financial performance into perspective. NASDAQ: ARDX. $4.76. …Nov 28, 2023 · Ardelyx Inc (NASDAQ:ARDX) trade information. Instantly ARDX has showed a red trend with a performance of -1.60% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.49 on Monday, 11/27/23 increased the stock’s daily price by 4.01%. According to Seeking Alpha data, Ardelyx's market cap of $864.92M shows decent market confidence, especially with its robust revenue growth forecasts: 2023 at …ARDELYX INC ( ARDX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...14 thg 9, 2023 ... Fintel reports that on September 13, 2023, Wedbush reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Outperform recommendation.Ardelyx Inc. (NASDAQ:ARDX) is a biopharmaceutical company based in Waltham, Massachusetts. The company develops and commercialized medicines to treat gastrointestinal and cardiorenal therapeutic ...
25 thg 9, 2023 ... Ardelyx's (NASDAQ:ARDX) Kidney Disease Therapy Bags Approval in Japan ... Ardelyx's lead candidate, tenapanor, has bagged approval in Japan for ...
S hares of Ardelyx ( NASDAQ: ARDX) were down 17% in afternoon trading Wednesday ahead of an expected FDA decision on its kidney disease treatment candidate Xphozah and amid a market-moving update ...Jul 18, 2021 · Ardelyx, Inc. (NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, develops ... On this news, the Company’s stock price fell $0.70, or 13.4%, to close at $4.51 per share on May 26, 2021, on unusually heavy trading volume.WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...According to 5 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price forecast is $8.7, which is an increase of 92.91% from the latest price.Ardelyx, Inc. Common Stock (ARDX). Nasdaq Listed ...Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 89.08% from the stock’s current price. A number of […]Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...
Ardelyx (NASDAQ:ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ...
(NASDAQ: ARDX) Ardelyx currently has 232,137,709 outstanding shares. With Ardelyx stock trading at $4.51 per share, the total value of Ardelyx stock (market …
NVIDIA Corporation Common Stock. $439.77 -0.64 -0.15%. VFS. VinFast Auto Ltd. Ordinary Shares. $8.11 +0.06 +0.75%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours ...Find the latest Institutional Holdings data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Ardelyx ( NASDAQ:ARDX – Get Free Report) ‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, …Ardelyx (NASDAQ:ARDX) is a biopharmaceutical innovator specializing in renal and cardiovascular care, driving novel therapeutic solutions forward.The stock has consistently shown a positive ...Dec 13, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ... Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ...Ardelyx ( NASDAQ:ARDX – Get Free Report) ‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, …Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Ardelyx, Inc. (NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, develops ...
About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ...Ardelyx (NASDAQ: ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy.Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...After Hours Volume: 64.24K. Close. Chg. Chg %. $4.3300. 0.3000. 7.44%. Ardelyx Inc. advanced stock charts by MarketWatch. View ARDX historial stock data and compare to other stocks and exchanges.Instagram:https://instagram. lithium stocks etfbot investmentbest dental plans in georgiaai software stocks Ardelyx, Inc. ( NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. business development classesarm ipo pricing WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ... stock comparison charts Mar 2, 2023 · Ardelyx (ARDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.31 per share a year ago. These figures are ... Ardelyx, Inc.'s (NASDAQ:ARDX) top owners are individual investors with 53% stake, while20% is held by institutions. Read full article. Simply Wall St. November 8, 2022 at 5:48 AM ...